Actively Recruiting
XOR Levels in OSA Patients (XOR-OSA)
Led by Nanjing Medical University · Updated on 2024-08-16
80
Participants Needed
1
Research Sites
78 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The level of xanthine oxidoreductase (XOR) in plasma is associated with oxidative stress and inflammation. Obstructive Sleep Apnea (OSA) is characterized by repeated upper airway obstruction and apneas during sleep, leading to chronic intermittent hypoxemia. The specific role of XOR in OSA, its relationship with the severity of OSA, and the changes in XOR levels before and after CPAP treatment remain unclear. The study will enroll 80 patients from the First Affiliated Hospital of Nanjing Medical University, categorized by their Apnea-Hypopnea Index (AHI) into mild, moderate, and severe OSA groups. Participants will undergo baseline assessments including polysomnography (PSG) and measurements of XOR activity and biomarkers such as uric acid, endothelin-1 (ET-1), endothelial nitric oxide synthase (eNOS), and inflammatory markers. Eligible patients will receive CPAP treatment for 3 months, after which their XOR activity and biomarker levels will be re-evaluated to assess treatment efficacy.
CONDITIONS
Official Title
XOR Levels in OSA Patients (XOR-OSA)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged between 18 and 80 years.
- Diagnosed with Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) with an apnea-hypopnea index of 5 or higher.
- First-time diagnosis with no previous surgical interventions or CPAP treatment for OSA.
- Ability and willingness to provide informed consent for participation in the study.
You will not qualify if you...
- History of severe stroke or cerebral hemorrhage, or presence of neurological or psychiatric conditions that could affect study results.
- Active malignancies or severe underlying diseases such as severe liver or kidney dysfunction.
- Diagnosed with diabetes or other significant vascular diseases.
- Severe chronic obstructive pulmonary disease (COPD), severe asthma, severe pulmonary hypertension, or heart failure.
- Pregnancy or other conditions making participation unsuitable.
- Extremely debilitated patients or those with severe underlying conditions.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210029
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here